Don't Buy Tandem Diabetes Care Until This Big Thing Happens

Tandem Diabetes Care (NASDAQ: TNDM), a medical device company, has had a rough year. The company's shares are down by 43%. It might be tempting to consider the stock at current levels. If it can perform well over the next few years, initiating a position today would yield excellent returns in the medium term. However, several factors need to align for Tandem Diabetes Care to become an attractive investment. Let's discuss one of those.Image source: Getty Images.Here's one thing no one can take away from Tandem Diabetes Care: It is a highly innovative company whose insulin pumps are among the market leaders. The company's t:slim X2 has been its main growth driver for a long time. This device is user-friendly, can pair with continuous glucose monitoring devices to automate insulin delivery, is significantly smaller than most competing ones, and supports remote updates. Besides its best-known product, Tandem Diabetes Care also launched the Tandem Mobi in the U.S. last year.Continue readingWeiter zum vollständigen Artikel bei MotleyFool Weiter zum vollständigen Artikel bei MotleyFool